Merck raised U.S. prices on five of its drugs in November by between 1.5% and 6%, the first increases since the drugmaker pledged it would not raise the average net price of all its medicines by more than the inflation rate, Reuters reports, citing a company spokeswoman. Merck raised the price of cancer immunotherapy Keytruda, which is expected to generate over $7B in sales this year, by roughly 1.5% as well as the price of its human papillomavirus vaccine Gardasil, which is forecast to bring in around $3B in sales, by about 6%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.